Wheatley-Price P, Navani V, Pabani A, Routy B, et al. Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT --> durvalumab in Canada: The RELEVANCE study. Lung Cancer 2025;204:108583.
PMID: 40393235